ABIOMED Stock News

Oct 09, 2020 (The Expresswire) -- Global “Chronic Heart Failure Market” is a comprehensive research that provides information regarding Chronic Heart Failure...

Les avantages d'une revascularisation plus complète avec les pompes cardiaques Impella chez les patients ayant reçu une intervention coronaire percuta

I vantaggi di una rivascolarizzazione più completa con le pompe intracardiache Impella nei pazienti ad alto rischio di intervento coronarico percutane

Handelsbanken Fonder AB acquired a new position in shares of ABIOMED, Inc. (NASDAQ:ABMD) during the second quarter, according to the company in its most recent 13F filing with the Securities and Excha

Glenmede Trust Co. NA reduced its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 15.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (S

Verition Fund Management LLC bought a new stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commi

Abiomed to hold fireside chat at the Raymond James North American Equities Conference.

Some of the names on this list may surprise you.

Amalgamated Bank decreased its position in ABIOMED, Inc. (NASDAQ:ABMD) by 60.8% in the second quarter, Holdings Channel reports. The institutional investor owned 2,957 shares of the medical equipment

Rafferty Asset Management LLC bought a new stake in ABIOMED, Inc. (NASDAQ:ABMD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought

Teza Capital Management LLC bought a new position in shares of ABIOMED, Inc. (NASDAQ:ABMD) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,11

North America is expected to be the most lucrative region in the global ischemia reperfusion injury therapeutics market during 2020-2027.

The S&P 500 closed at a record high on Tuesday, wiping out losses from the coronavirus-induced selloff, but new analysis shows most stocks have yet to climb back to prior levels.

ABIOMED, Inc. (NASDAQ:ABMD) Director Martin P. Sutter sold 750 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $311.99, for a to